Inhaled Insulin: A New Modality for Management of Diabetes

- NEW DELHI, INDIA, July 12, 2006 - Victimizing more than 194Mn people all over the world, diabetes has surfaced as one of the most fatal diseases known to man. As a consequence of growing cases of diabetes, innovative & effective therapeutic options are desperately needed by both medical fraternity and patients.

Various pharmaceutical companies are engaged in researching and developing the most accurate & effective therapeutic options for the disease. The latest addition to this continuous endeavor is an innovative product by Pfizer, a leading pharmaceutical company. Pfizer has announced that it"ll launch its latest product Exubera (inhaled insulin) in July 2006. The product will be available throughout the United States.

"New Developments in Insulin Delivery Systems (2006)", a recently published market research report by RNCOS, includes an in-depth analysis of every relevant issue related to the insulin deliver systems. Not only does it provide the information on the current developments taking place in the industry, it also includes a discussion on the causes & symptoms of the disease.

As per the research, "About 18Mn, out of the total 165Mn diabetic patients across the world, are in USA alone. About 5% of these patients suffer from Type 1 diabetes (also known as "Juvenile diabetes"). Type 1 diabetes is mainly caused by the destruction of the islet cells (insulin producing cells). However rest of them have Type 2 diabetes, characterized by body"s inability to take advantage of the insulin that"s available. The main causes of Type 2 diabetes are obesity, aging & physical inactivity".

Main features of the report

§ Information about the traditional and non-traditional therapies to help in comparative analysis of the industry.
§ Market sizing and growth rate of insulin delivery market across USA, Western Pacific, South and Central America, Europe and Asia.
§ Analysis of the diabetes drug market across the globe.
§ Profile discussion of key players such as Eli Lilly & Company, Sanofi-Aventis, GlaxoSmithKline plc, Novo Nordisk A/S, Amylin Pharmaceuticals etc.
§ Reliable predictions about the industry in the years to come.

To purchase your copy: http://www.marketsmonitor.com/category/IM040.html />For more information about the report please visit www.marketsmonitor.com

12.07.2006 - 22:56 Quelle: 24-7pressrelease.com | Gelesen: 83 X